Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–117

Article  CAS  PubMed  Google Scholar 

Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int. 2015;35(Suppl 1):78–81

Article  PubMed  Google Scholar 

Chen S, Zhou J, Wu X, Meng T, Wang B, Liu H, et al. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int. 2021;15:611–620

Article  PubMed  Google Scholar 

Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, et al. Long-term telbivudine treatment results in resolution of liver inflammation and fibrosis in patients with chronic hepatitis B. Adv Ther. 2015;32:727–741

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893

Article  CAS  PubMed  Google Scholar 

Sun Y, Wu X, Zhou J, Meng T, Wang B, Chen S, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy. Clin Gastroenterol Hepatol. 2020;18:2582-2591.e6

Article  CAS  PubMed  Google Scholar 

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475

Article  CAS  PubMed  Google Scholar 

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455

Article  CAS  PubMed  Google Scholar 

Xu S, Wang Y, Tai DCS, Wang S, Cheng CL, Peng Q, et al. qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients. J Hepatol. 2014;61:260–269

Article  PubMed  PubMed Central  Google Scholar 

Lefkowitch JH. Scheuer’s Liver Biopsy Interpretation. 9th ed. Edinburgh: Elsevier; 2015. p. 11–16

Google Scholar 

Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699

Article  CAS  PubMed  Google Scholar 

Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65:1438–1450

Article  CAS  PubMed  Google Scholar 

Theise ND, Jia J, Sun Y, Wee A, You H. Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. Mod Pathol. 2018;31:1191–1200

Article  PubMed  Google Scholar 

Tai DC, Tan N, Xu S, Kang CH, Chia SM, Cheng CL, et al. Fibro-C-Index: comprehensive, morphology-based quantification of liver fibrosis using second harmonic generation and two-photon microscopy. J Biomed Opt. 2009;14:044013

Article  PubMed  Google Scholar 

Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847

Article  PubMed  Google Scholar 

Pérez-Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu. 1979;14(Pt 2):183–213

PubMed  Google Scholar 

Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124:1599–1607

Article  CAS  PubMed  Google Scholar 

Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008;103:2776–2783

Article  CAS  PubMed  Google Scholar 

Surana P, Kapuria D, Broadwell C, Wright EC, Takyar V, Kleiner DE, et al. Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years. Antiviral Res. 2019;168:61–67

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773–780

Article  CAS  PubMed  Google Scholar 

Kong Y, Sun Y, Zhou J, Wu X, Chen Y, Piao H, et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. J Viral Hepat. 2019;26:576–585

Article  CAS  PubMed  Google Scholar 

Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl). 2020;133:1696–1702

Article  CAS  PubMed  Google Scholar 

Wanless IR. In Reply. Arch Pathol Lab Med. 2000;124:1592–1593

Article  Google Scholar 

Wanless I, Wang B, Sun Y, You H, Jia J, Chen S, et al. THU-381-Characterization of regeneration in chronic hepatitis B before and after entecavir treatment in 20 patients. J Hepatol. 2019;70:e322

Article  Google Scholar